Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2011 annual average exchange rates.
The Belgian biotechnology market had total revenue of $5,944.6 million in 2010, representing a compound annual growth rate (CAGR) of 11.1% between 2006 and 2010.
Medical/Healthcare sales proved the most lucrative for the Belgian biotechnology market in 2010, with total revenues of $4,608.9 million, equivalent to 77.5% of the market's overall value.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.6% for the five-year period 2010 - 2015, which is expected to drive the market to a value of $8,165.1 million by the end of 2015.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Belgium

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Belgium

Leading company profiles reveal details of key biotechnology market players' global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Belgium biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Belgium economy

Key Questions Answered

What was the size of the Belgium biotechnology market by value in 2010?

What will be the size of the Belgium biotechnology market in 2015?

What factors are affecting the strength of competition in the Belgium biotechnology market?

How has the market performed over the last five years?

What are the main segments that make up Belgium's biotechnology market?

EXECUTIVE SUMMARY
MARKET OVERVIEW
- Market definition
- Research highlights
- Market analysis
MARKET VALUE
MARKET SEGMENTATION I
MARKET SEGMENTATION II
FIVE FORCES ANALYSIS
- Summary
- Buyer power
- Supplier power
- New entrants
- Substitutes
- Rivalry
LEADING COMPANIES
- Astra Zeneca
- Novartis AG
- Sanofi-Aventis Group
- ThromboGenics
MARKET FORECASTS
- Market value forecast
MACROECONOMIC INDICATORS
APPENDIX
- Methodology
- Industry associations
- Related Datamonitor research
- Disclaimer
ABOUT DATAMONITOR
- Premium Reports
- Summary Reports
- Datamonitor consulting
LIST OF TABLES
- Table 1: Belgium biotechnology market value: $ million, 2006-10
- Table 2: Belgium biotechnology market segmentation I:% share, by value, 2010
- Table 3: Belgium biotechnology market segmentation II: % share, by value, 2010
- Table 4: Astra Zeneca: key facts
- Table 5: Astra Zeneca: key financials ($)
- Table 6: Astra Zeneca: key financial ratios
- Table 7: Novartis AG: key facts
- Table 8: Novartis AG: key financials ($)
- Table 9: Novartis AG: key financial ratios
- Table 10: Sanofi-Aventis Group: key facts
- Table 11: Sanofi-Aventis Group: key financials ($)
- Table 12: Sanofi-Aventis Group: key financials (€)
- Table 13: Sanofi-Aventis Group: key financial ratios
- Table 14: ThromboGenics: key facts
- Table 15: Belgium biotechnology market value forecast: $ million, 2010-15
- Table 16: Belgium size of population (million), 2006-10
- Table 17: Belgium gdp (constant 2000 prices, $ billion), 2006-10
- Table 18: Belgium gdp (current prices, $ billion), 2006-10
- Table 19: Belgium inflation, 2006-10
- Table 20: Belgium consumer price index (absolute), 2006-10
- Table 21: Belgium exchange rate, 2006-10
LIST OF FIGURES
- Figure 1: Belgium biotechnology market value: $ million, 2006-10
- Figure 2: Belgium biotechnology market segmentation I:% share, by value, 2010
- Figure 3: Belgium biotechnology market segmentation II: % share, by value, 2010
- Figure 4: Forces driving competition in the biotechnology market in Belgium, 2010
- Figure 5: Drivers of buyer power in the biotechnology market in Belgium, 2010
- Figure 6: Drivers of supplier power in the biotechnology market in Belgium, 2010
- Figure 7: Factors influencing the likelihood of new entrants in the biotechnology market in Belgium, 2010
- Figure 8: Factors influencing the threat of substitutes in the biotechnology market in Belgium, 2010
- Figure 9: Drivers of degree of rivalry in the biotechnology market in Belgium, 2010
- Figure 10: Astra Zeneca: revenues & profitability
- Figure 11: Astra Zeneca: assets & liabilities
- Figure 12: Novartis AG: revenues & profitability
- Figure 13: Novartis AG: assets & liabilities
- Figure 14: Sanofi-Aventis Group: revenues & profitability
- Figure 15: Sanofi-Aventis Group: assets & liabilities
- Figure 16: Belgium biotechnology market value forecast: $ million, 2010-15

Pharmaceutical Market Research

Biotechnology in Belgium